De novo design TNF-α antagonistic peptide based on the complex structure of TNF-α with its neutralizing monoclonal antibody Z12

Journal of Biotechnology

Volumn 125, Issue 1, 2006, Pages 57-63

  Qin, Weisong ^a   Feng, Jiannan ^a   Li, Yan ^a   Lin, Zhou ^a   Shen, Beifen ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Antagonistic peptide; De novo design; Molecular modeling; TNF

Indexed keywords

AMINO ACIDS; ANTIBODIES; CYTOLOGY; DISEASES; MOLECULAR WEIGHT; TOXICITY;

ANTAGONISTIC PEPTIDE; DE NOVO DESIGN; MOLECULAR MODELING; TNF-Α;

PROTEINS;

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Z12; PEPTIDE; SERYLSERYLTYROSYLPROLYLGLYCYLTYROSYLSERYLGLUTAMINYLPROLYLTHREONYLARGINYL SERYLTYROSYLPROLYLSERINE CARBOXAMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONISTIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVATION; MATHEMATICAL MODEL; MOLECULAR MIMICRY; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTIBODIES, MONOCLONAL; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MODELS, MOLECULAR; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 33746002602     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2006.01.036     Document Type: Article

References (40)

1. Antoni C., and Braun J. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20 (2002) S152-S157
2. Balkwill F.R., and Burke F. The cytokine network. Immunol. Today 109 (1989) 299-304
3. Banner D.W., D'Arcy A., James W., Gentz R., Schoenfeld H.J., Broger C., Loetscher H., and Lesslauer W. Crystal structure of the soluble human 55 kDa TNF receptor-human TNF-α complex: implications for TNF receptor activation. Cell 73 (1993) 431-445
4. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334 (1996) 1717-1725
5. Beutler B., and Cerami A. The biology of cachetin/TNF a primary mediator of the host response. Annu. Rev. Immunol. 7 (1989) 625-655
6. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 26 (1999) 16-21
7. Braun J., and Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3 (2003) 141-168
8. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., and Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3127-3131
9. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., and Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288 (2000) 2351-2354
10. Chirinos-Rojas C.L., Steward M.W., and Partidos C.D. A peptidomimetic antagonist of TNF-α mediated cytotoxicity identified from a phage-displayed random peptide library. J. Immunol. 161 (1998) 5621-5626
11. Debandt M., Vittecoq O., Descamps V., Le Loet X., and Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin. Rheumatol. 22 (2003) 56-61
12. Dembic Z., Loetscher H., Gubler U., Pan Y.C., Lahm H.W., Gentz R., Brockhaus M., and Lesslauer W. Two human TNF receptors have similar extracellular but distinct intracellular domain sequences. Cytokine 2 (1990) 231-237
13. Devos S.A., Van Den Bossche N., Devos M., and Naeyaert J.M. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206 (2003) 388-390
14. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 19 (2001) 163-196
15. Feldmann M., and Maini R.N. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2 (2002) 364-371
16. Goffe B., and Cather J.C. Etanercept: an overview. J. Am. Acad. Dermatol. 49 (2003) S105-S111
17. Goldbach-Mansky R., and Lipsky P.E. New concepts in the treatment of rheumatoid arthritis. Annu. Rev. Med. 54 (2003) 197-216
18. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., and Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N. Engl. J. Med. 345 (2001) 1098-1104
19. Kieber-Emmons T., and Kohler H. Towards a unified theory of immunoglobulin structure-function relations. Immunol. Rev. 90 (1986) 29-48
20. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., and Gottlieb A.B. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349 (2003) 2014-2022
21. Lewis M., Tartaglia L.A., Lee A., Bennett G.L., Rice G.C., Wong G.H.W., et al. Cloning and expression and cross-linking analysis of the murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2830-2834
22. Lie B.L., Tunemoto D., Hemmi H., Mizukami Y., Fukuda H., Kikuchi H., et al. Identification of the binding site of 55 kDa tumor necrosis factor receptor by synthetic peptides. Biochem. Biophys. Res. Commun. 188 (1992) 503-509
23. Lipsky P.E., van der Heijde D.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1594-1602
24. O'Dell J.R. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2591-2602
25. Qin W., Feng J., Zhang W., Li Y., and Shen B. A novel TNFα antagonizing peptide-Fc fusion protein designed based on CDRs of TNFα neutralizing monoclonal antibody. Biochem. Biophys. Res. Commun. 322 (2004) 1024-1028
26. Qin W., Feng J., Li Y., Lin Z., and Shen B. Fusion protein of CDR mimetic peptide with Fc inhibit TNF-α induced cytotoxicity. Mol. Immunol. 43 (2006) 660-666
27. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50 (2000) 229-235
28. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
29. Seckinger P., Isaaz S., and Dayer J.M. Purification and biologic characterization of a specific tumor necrosis factor-α inhibitor. J. Biol. Chem. 264 (1989) 11966-11973
30. Smyth M.J., and Johnstone R.W. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc. Res. Tech. 50 (2000) 196-208
31. Steed P.M., Tansey M.G., Zalevsky J., Zhukovsky E.A., Desjarlais J.R., Szymkowski D.E., et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301 (2003) 1895-1898
32. Takasaki W., Kajino Y., Kajino K., Murali R., and Greene M.I. Structure based design and characterization of exocyclic peptidomimetics that inhibit TNF-α binding to its receptor. Nat. Biotechnol. 15 (1997) 1266-1270
33. Taub R., and Green M.I. Functional validation of ligand mimicry by anti-receptor antibodies: structural and therapeutic implications. Biochemistry 31 (1992) 7431-7435
34. Taylor S.I. Rational design of peptide agonists of cell-surface receptors. Trends in pharmacological. Sciences 21 (2000) 9-10
35. Weiner S.J., Kollman P.A., Nguyen D.T., and Case D.A. An all atom forcefield for simulations of proteins and nucleic acids. J. Comput. Chem. 7 (1986) 230-252
36. William V.W., Thomas K.E., Joan V., Mark I.G., and David B.W. Design of bioactive peptides based on antibody hypervariable region structures. J. Biol. Chem. 266 (1991) 5182-5190
37. Williams W., Guy H., Rubin D., Robey F., Myers J., Kieber-Emmons T., et al. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6488-6492
38. Williams W.V., Moss D.A., Kieber-Emmons T., Cohen J.A., Myers J.N., Weiner D.B., et al. Development of biologically active peptides based on antibody structure. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5537-5541
39. Wolf R., Matz H., Orion E., and Ruocco V. Anti-TNF therapies-the hope of tomorrow. Clin. Dermatol. 20 (2002) 522-530
40. Zhang W., Feng J., and Shen B. Identification of binding epitope of a monoclonal antibody (Z12) against human TNF-α using computer modeling and deletion mutant technique. Sci. China Ser. C 47 (2004) 167-174